News Conference News ACC 2023 No Downside to Immediate Complete Revascularization in ACS: BIOVASC Michael O'Riordan March 06, 2023
News Conference News ACC 2022 No Difference in 1-Year QoL Between FFR-Guided PCI and CABG: FAME-3 Michael O'Riordan April 13, 2022
News Conference News ACC 2022 Managing AF Patients Undergoing PCI—Some Lingering Questions Michael O'Riordan April 12, 2022
News Conference News ACC 2021 Complete Revascularization Analysis of ISCHEMIA Opens ‘Pandora’s Box’ Michael O'Riordan May 18, 2021
News Conference News ACC 2020 TICO: Ticagrelor Monotherapy After 3 Months of DAPT Curbs Bleeding in Stented ACS Patients Todd Neale March 31, 2020
News Conference News ACC 2020 VOYAGER PAD: Rivaroxaban Bests Aspirin Alone for Preventing Limb and CV Events L.A. McKeown March 28, 2020
News Conference News ACC 2019 Ticagrelor Monotherapy Noninferior to DAPT After PCI in Adjudicated-Events Analysis: GLASSY Yael L. Maxwell March 27, 2019
News Conference News ACC 2019 SAFARI Surprise: No Survival or Bleeding Advantage With Radial Over Femoral Access in STEMI Michael O'Riordan March 18, 2019
News Conference News ACC 2017 ABSORB III: Two-Year Results Show a Higher MACE Rate Compared With Xience Michael O'Riordan March 18, 2017
News Conference News ACC 2017 iFR Matches FFR for Clinical Outcomes in Patients With Intermediate Lesions Caitlin E. Cox March 18, 2017
News Conference News ACC 2012 RESOLUTE: Zotarolimus-Eluting Stent Fares Well at 2 Years March 26, 2012
News Conference News ACC 2012 Three Months of Antiplatelet Therapy with Endeavor Equal to 1 Year with Other DES Jason Kahn March 24, 2012